Enhertu 100mg

Enhertu 100 mg powder for concentrate for solution for infusion, 1 vial, Daiichi Sankyo. Indications: Enhertu is an anticancer medicine containing the active substance trastuzumab deruxtecan. One part of the medicine is a monoclonal antibody that specifically binds to cells that have the HER2 protein on their surface (HER2 positive), as some cancer cells do. The other active part of Enhertu is DXd, a substance that destroys cancer cells. Once the medicine binds to HER2 positive cancer cells, DXd enters the cells and destroys them. What Enhertu is used for: Enhertu is used for the treatment of adults who have: • HER2 positive breast cancer that has spread to other parts of the body (metastatic disease) or that cannot be removed surgically and who have tried one or more specific treatments for HER2 positive breast cancer. • HER2 low breast cancer that has spread to other parts of the body (metastatic disease) or that cannot be removed surgically and who have been given previous treatment for metastatic disease or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). A test will be performed to ensure Enhertu is right for you. • HER2 positive gastric cancer that has spread to other parts of the body or to areas adjacent to the stomach that cannot be removed surgically and who have tried another specific treatment for HER2 positive gastric cancer. Contraindications: You must not be given Enhertu if you are allergic to trastuzumab deruxtecan or any of the other ingredients of this medicine. Precautions: Before you are given Enhertu, talk to your doctor or pharmacist. Enhertu can cause serious side effects including lung problems, heart problems, infusion reactions, low blood cell counts, liver problems, and digestive system problems. Monitor for new or worsening symptoms. Pregnancy, breastfeeding and fertility: • Pregnancy: Enhertu is not recommended during pregnancy as this medicine may harm your unborn baby. Talk to your doctor immediately if you are pregnant, think you may be pregnant, or intend to become pregnant before or during treatment. • Breastfeeding: Do not breastfeed during treatment with Enhertu and for at least 7 months after the last dose. This is because it is not known if Enhertu passes into breast milk. Discuss this with your doctor. • Contraception: Use effective contraceptive methods to avoid pregnancy while being treated with Enhertu. Women being given Enhertu should continue to use contraceptive methods for at least 7 months after the last dose of Enhertu. Men being given Enhertu who have partners of childbearing potential should use effective contraceptive methods during treatment and for at least 4 months after the last dose of Enhertu. Talk to your doctor about the most appropriate contraceptive method for you. Also talk to your doctor before you stop using your contraceptive method. • Fertility: If you are male and being treated with Enhertu, you should not father a child for 4 months after treatment and should seek advice on sperm preservation before treatment, as the medicine may reduce your fertility. Therefore, discuss this with your doctor before starting treatment. Driving and using machines: Enhertu is unlikely to reduce your ability to drive or use machines. Be careful if you experience tiredness, dizziness or headache. Administration: Enhertu will be given to you in a hospital or clinic: • The recommended dose of Enhertu for treatment of: HER2 positive or HER2 low breast cancer is 5.4 mg per kilogram of body weight, once every 3 weeks; HER2 positive gastric cancer is 6.4 mg per kilogram of body weight, once every 3 weeks. • Your doctor or nurse will give you Enhertu through an infusion (drip) into a vein. • The first infusion will be given over 90 minutes. If this goes well, the infusion at your next visits may be given over 30 minutes. • Your doctor will decide how many treatments you need. • Before each infusion with Enhertu, your doctor may give you medicines to prevent nausea and vomiting. • If you have symptoms associated with the infusion, your doctor or nurse may reduce the infusion rate or may interrupt or stop your treatment. • Before and during treatment with Enhertu, your doctor will perform tests which may include: blood tests to check blood cell counts, liver and kidneys; tests to check your heart and lungs. • Your doctor may reduce your dose or temporarily interrupt or permanently stop treatment, depending on your adverse reactions. Composition: Active substance: trastuzumab deruxtecan. One vial of powder for concentrate for solution for infusion contains 100 mg trastuzumab deruxtecan. After reconstitution, one 5 mL vial of solution contains 20 mg/mL trastuzumab deruxtecan. Other ingredients: L-histidine, L-histidine hydrochloride monohydrate, sucrose, polysorbate 80. Package: 1 vial Warning: Read the package leaflet carefully before use. This summary is not complete. Always consult full prescribing information and your healthcare provider. Enhertu 100 mg powder for concentrate for solution for infusion, 1 vial, Daiichi Sankyo (trastuzumab deruxtecan) belongs to the group of medicines: antineoplastics. Regulatory Disclaimer: This listing is for informational purposes only. Supply restricted to authorized channels where legally permitted. Consult your oncologist for individualized treatment decisions.